XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We have one operating segment and one reportable segment as our CODM, reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. The performance measure closest to U.S. GAAP used by our CODM to evaluate the performance of the Company’s ongoing operations on a consolidated basis and as part of the Company’s internal planning and forecasting activities is net loss attributable to common shareholders of Evolent Health, Inc. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements.
The following table presents our revenue and significant expenses reviewed by our CODM, other segment items and net loss attributable to common shareholders of Evolent Health, Inc. (in thousands):
For the Three Months Ended March 31,
20252024
Revenue$483,649 $639,653 
Less:
Medical expense and device costs292,676 431,336 
Cost of revenue excluding medical expense and device costs and other segment items (1)
87,845 103,206 
Selling, general and administrative expenses excluding other segment items (2)
66,268 51,014 
Depreciation and amortization expenses24,058 29,503 
Interest income(1,274)(2,550)
Interest expense10,385 5,997 
(Gain) loss from equity method investees19 (306)
Provision from income taxes1,470 565 
Change in tax receivables agreement liability— 173 
Other segment items (3)
74,452 45,940 
Net loss attributable to common shareholders of Evolent Health, Inc.$(72,250)$(25,225)
————————
(1)Other segment items excluded from cost of revenue excluding medical expense and device costs include $0.7 million and $1.0 million of stock compensation for the three months ended March 31, 2025 and 2024, respectively.
(2)Other segment items excluded from selling, general and administrative expenses include $10.4 million and $17.8 million of stock compensation, $1.0 million and $0.4 million of severance costs, $0.7 million and $— million of transaction-related costs and $— million and $9.9 million of repositioning costs for the three months ended March 31, 2025 and 2024, respectively.
(3)Other segment items is defined as stock-based compensation, severance costs, transaction-related costs and repositioning costs not included in cost of revenue or selling, general and administrative expenses calculated in accordance with GAAP, loss on lease termination, change in fair value of contingent consideration, loss on option exercise, other income (expense), net, and dividends and accretion of Series A Preferred Stock. Management believes cost of revenue excluding medical expense and device costs and other segment items and selling, general and administrative expenses excluding other segment items are useful to investors because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.